Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2007-12-04

Last Posted Date: 2018-12-11

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 100

Registration Number: NCT00567359

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 5 locations

Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Erlotinib
Drug: Oxaliplatin

First Posted Date: 2007-11-28

Last Posted Date: 2013-02-15

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 140

Registration Number: NCT00564720

Locations: 🇬🇷
Metaxa's Anticancer Hospital of Piraeus, 1st Department of Medical Oncology, Athens, Greece
🇬🇷
University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupolis, Greece
🇬🇷
Errikos Ntynan General Hospital, Athens, Greece

and more 5 locations

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Erlotinib
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2007-11-26

Last Posted Date: 2019-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT00563784

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: bevacizumab
Drug: Erlotinib

First Posted Date: 2007-11-06

Last Posted Date: 2022-07-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 32

Registration Number: NCT00553800

Locations: 🇺🇸
AtlantiCare Regional Medical Center, Galloway, New Jersey, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Virtua Health Cancer Program at Memorial, Mount Holly, New Jersey, United States

and more 4 locations

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: erlotinib

First Posted Date: 2007-10-29

Last Posted Date: 2013-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 247

Registration Number: NCT00550173

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib
Radiation: SBRT

First Posted Date: 2007-10-22

Last Posted Date: 2020-08-21

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 24

Registration Number: NCT00547105

Locations: 🇺🇸
University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States
🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Phase 1

Completed

Conditions: Rectal Cancer

Interventions: Drug: Bevacizumab
Drug: Capecitabine
Drug: Erlotinib
Radiation: Radiation Therapy
Procedure: Surgery

First Posted Date: 2007-10-15

Last Posted Date: 2015-02-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00543842

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab in Multiple Phase I Combinations

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Bevacizumab
Drug: Sunitinib
Drug: Sorafenib
Drug: Erlotinib
Drug: Trastuzumab
Drug: Cetuximab
Drug: Lapatinib

First Posted Date: 2007-10-15

Last Posted Date: 2020-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 343

Registration Number: NCT00543504

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Esophageal Cancer

Interventions: Drug: Erlotinib
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2007-10-04

Last Posted Date: 2020-03-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 7

Registration Number: NCT00539617

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Erlotinib
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2007-09-28

Last Posted Date: 2013-06-12

Lead Sponsor: Aktion Bronchialkarzinom e.V.

Target Recruit Count: 224

Registration Number: NCT00536640

Locations: 🇩🇪
Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
🇩🇪
Asklepios Klinik Harburg, Hamburg, Germany
🇩🇪
Charite´ Mitte, Berlin, Germany

and more 34 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy